Filing Flows › Arcadia Biosciences (RKDA) › Q4 2025
Arcadia Biosciences (RKDA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Arcadia Biosciences (RKDA) reported revenue of $901K for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and -31% from the quarter before. Operating margin was -152.6%, net loss $1.3M (144.0% of revenue).
Arcadia Biosciences, Q4 2025: revenue $901K (-26% year over year), operating margin -152.6%, net loss $1.3M, operating cash flow −$822K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $901K | -31% | -26% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.3M | -252% | — |
| Operating cash flow | −$822K | — | — |
What changed
Revenue was $901K in Q4 2025, down 26% year over year and down 31% from the previous quarter.
Operating costs exceeded revenue by $1.4M, an operating margin of -152.6%. Total costs fell 35% while revenue fell 26%. The quarter ended with a net loss of $1.3M, after a profit of $856K the previous quarter.
Operating cash flow was −$822K. Non-cash charges added back $2K of depreciation and $17K of share-based compensation. Working capital and other items added $456K.
Questions
What was Arcadia Biosciences' revenue in the fourth quarter 2025?
Arcadia Biosciences (RKDA) reported revenue of $901K for the fourth quarter 2025 (Q4 2025), -26% from a year earlier and -31% from the quarter before.
Was Arcadia Biosciences profitable in the fourth quarter 2025?
Operating loss was $1.4M (-152.6% of revenue) and net loss $1.3M.